Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne Cheng

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Diabetes|March 1, 2007
Polymorphisms of the renin-angiotensin system genes predict progression of subclinical coronary atherosclerosisAdam Kretowski, Kim McFann, John E Hokanson, et al.
Stroke|January 10, 2009
A meta-analysis of candidate gene polymorphisms and ischemic stroke in 6 study populations: association of lymphotoxin-alpha in nonhypertensive patientsXingyu Wang, Suzanne Cheng, Victoria H Brophy, et al.
The Lancet. Oncology|February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A McArthur, Paul B Chapman, Caroline Robert, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Diabetes|March 1, 2007
Polymorphisms of the renin-angiotensin system genes predict progression of subclinical coronary atherosclerosisAdam Kretowski, Kim McFann, John E Hokanson, et al.
Stroke|January 10, 2009
A meta-analysis of candidate gene polymorphisms and ischemic stroke in 6 study populations: association of lymphotoxin-alpha in nonhypertensive patientsXingyu Wang, Suzanne Cheng, Victoria H Brophy, et al.
The Lancet. Oncology|February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A McArthur, Paul B Chapman, Caroline Robert, et al.
Pageof 7